Opinion: All Covid-19 Vaccines Are Equally Worthy of Your Arm
Headlines about the Johnson & Johnson trial results cite an efficacy rate lower than Pfizer’s and Moderna’s. But one figure doesn’t tell the whole story.
Related Articles
Gilead Sciences : Submits New Drug Application to U.S. Food and Drug Administration for Twice-Yearly Lenacapavir for HIV Prevention
Lenacapavir Named 2024 Breakthrough of the Year by Science Magazine Foster City, Calif., December 19, 2024 – Gilead Sciences, Inc. today announced the company completed…
Endemic – Mayo Clinic Press
Endemic aims squarely at reckoning with comprehending and living with a new respiratory disease and how to face the coming variants. Order your copy today!
Researchers Release Study Analyzing Global Learning Crisis Post-COVID
Data show that achievement levels worldwide are often lower than expected for schools that had prolonged closures during COVID-19, and researchers note specifically the vulnerabilities…
Polio vaccine isn’t going anywhere, Trump says
“You’re not going to lose the polio vaccine,” Trump said during a press conference Monday. “That’s not gonna happen.”
Endemic – Mayo Clinic Press
Endemic aims squarely at reckoning with comprehending and living with a new respiratory disease and how to face the coming variants. Order your copy today!
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
The Urgent Case for Recommitting to Global HIV/AIDS Goals
This Viewpoint discusses the need to recommit to the fight against HIV/AIDS to reach the United Nation’s 2030 goal of ending the epidemic as a…
The Urgent Case for Recommitting to Global HIV/AIDS Goals
This Viewpoint discusses the need to recommit to the fight against HIV/AIDS to reach the United Nation’s 2030 goal of ending the epidemic as a…
NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain
Tecovirimat was safe but did not reduce the time to lesion resolution or reduce pain among adults with mild to moderate clade II mpox and…